Immunic Target of Unusually High Options Trading (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) saw some unusual options trading activity on Tuesday. Stock investors bought 2,229 call options on the stock. This represents an increase of approximately 849% compared to the typical volume of 235 call options.

Immunic Price Performance

NASDAQ:IMUX opened at $1.20 on Thursday. The business’s 50-day simple moving average is $1.07 and its 200-day simple moving average is $1.21. Immunic has a fifty-two week low of $0.92 and a fifty-two week high of $2.11. The stock has a market capitalization of $108.09 million, a PE ratio of -0.98 and a beta of 1.89.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. State Street Corp increased its position in shares of Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares in the last quarter. 683 Capital Management LLC boosted its stake in Immunic by 2.2% in the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after purchasing an additional 15,349 shares during the period. Bridgeway Capital Management LLC increased its holdings in Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after purchasing an additional 22,200 shares in the last quarter. Focus Partners Wealth raised its stake in shares of Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after purchasing an additional 23,610 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Immunic in the third quarter valued at about $50,000. Institutional investors own 51.82% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. William Blair started coverage on Immunic in a research report on Tuesday. They set an “outperform” rating for the company. D. Boral Capital reiterated a “buy” rating and issued a $17.00 price target on shares of Immunic in a research report on Wednesday, February 26th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Immunic in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $12.67.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.